2022 SITC Poster #51: A combination of antigen presentation and T-cell recognition features improves neoantigen immunogenicity predictions


Tumor neoantigen burden outperforms tumor mutational burden (TMB) in prediction of patient response to immune checkpoint blockade (ICB) therapy by better capturing the biological mechanism underlying response [1]. However, immune recognition of neoantigens by T-cells requires more than antigen presentation, which has been the focus of tumor neoantigen burden thus far. To address this need, we extend the existing SHERPA™ MHC-presentation framework [2] to predict neoantigen immunogenicity.